Received May 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MMRV | MEASLES + MUMPS + RUBELLA + VARICELLA (PROQUAD) | MERCK & CO. INC. | UNK | Y015992 | — |
No adverse effects reported. No other information provided. No additional AE.; HCP reports 66 year old female received pediatric dose of PROQUAD instead standard dose of MMR II.; This spontaneous report was received from a medical assistant and refers to a 66-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On 17-APR-2025, the patient was vaccinated with Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (PROQUAD), lot #Y015992; which has been verified to be valid for Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live, expiration date reported as 32-MAR-2026 but upon internal validation establish as 23-Mar-2026 administered for prophylaxis (strength, exact quantity volume, dose number, route and anatomical site of administration were not provided) with the sterile diluent (BAXTER STERILE DILUENT) (lot # and expiration date were not reported) instead of standard dose of Measles, Mumps, and Rubella (Wistar RA 27-3) Virus Vaccine, Live (M-M-R II) with the sterile diluent (BAXTER STERILE DILUENT) (Wrong product administered). No adverse effects reported. No other information provided (No adverse event).
Sterile diluent